[1]
|
Stepanova, M., Sayiner, M., de Avila, L., Younoszai, Z., Racila, A. and Younossi, Z.M. (2016) Long-Term Outcomes of Liver Transplantation in Patients with Hepatitis C Infection Are Not Affected by HCV Positivity of a Donor. BMC Gastroenterology, 16, 137. https://doi.org/10.1186/s12876-016-0551-z
|
[2]
|
Goldberg, D.S., Blumberg, E., McCauley, M., Abt, P. and Levine, M. (2016) Improving Organ Utilization to Help Overcome the Tragedies of the Opioid Epidemic. American Journal of Transplantation, 16, 2836-2841.
https://doi.org/10.1111/ajt.13971
|
[3]
|
Gonzalez, S.A. and Trotter, J.F. (2018) The Rise of the Opioid Epidemic and Hepatitis C-Positive Organs: A New Era in Liver Transplantation. Hepatology, 67, 1600-1608. https://doi.org/10.1002/hep.29572
|
[4]
|
Kreitman, K.R., Kothadia, J.P., Nair, S.P. and Maliakkal, B.J. (2021) Unexpected Hepatitis B Virus Transmission after Liver Transplant from Nucleic Acid Testing- and Serology-Negative Liver Donors Who Are Hepatitis C Viremic. Hepatology Research, 51, 1242-1246. https://doi.org/10.1111/hepr.13680
|
[5]
|
Kim, W.R., Lake, J.R., Smith, J.M., et al. (2018) OPTN/SRTR 2016 Annual Data Report: Liver. American Journal of Transplantation, 18, 172-253. https://doi.org/10.1111/ajt.14559
|
[6]
|
Kwo, P.Y. and Badshah, M.B. (2015) New Hepatitis C Virus Therapies: Drug Classes and Metabolism, Drug Interactions Relevant in the Transplant Settings, Drug Options in Decompen-sated Cirrhosis, and Drug Options in End-Stage Renal Disease. Current Opinion in Organ Transplantation, 20, 235-241.
https://doi.org/10.1097/MOT.0000000000000198
|
[7]
|
Cotter, T.G., Paul, S., Sandikci, B., et al. (2019) Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors. Hepatology, 69, 2381-2395. https://doi.org/10.1002/hep.30540
|
[8]
|
Aslam, S., Grossi, P., Schlendorf, K.H., et al. (2020) Utiliza-tion of hepatitis C Virus-Infected Organ Donors in Cardiothoracic Transplantation: An ISHLT Expert Consensus Statement. The Journal of Heart and Lung Transplantation, 39, 418-432. https://doi.org/10.1016/j.healun.2020.03.004
|
[9]
|
Durand, C.M., Bowring, M.G., Thomas, A.G., et al. (2018) The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States: A National Registry Study. Annals of Internal Medicine, 168, 702-711.
https://doi.org/10.7326/M17-2451
|
[10]
|
Kwong, A.J., Wall, A., Melcher, M., et al. (2019) Liver Transplantation for Hepatitis C Virus (HCV) Non-Viremic Recipients with HCV Viremic Donors. American Journal of Transplanta-tion, 19, 1380-1387.
https://doi.org/10.1111/ajt.15162
|
[11]
|
Bunchorntavakul, C. and Reddy, K.R. (2016) Treat Chronic Hepatitis C Virus Infection in Decompensated Cirrhosis—Pre- or Post-Liver Transplantation? The Ironic Conundrum in the Era of Effective and Well-Tolerated Therapy. Journal of Viral Hepatitis, 23, 408-418. https://doi.org/10.1111/jvh.12534
|
[12]
|
Bari, K., Luckett, K., Kaiser, T., et al. (2018) Hepatitis C Transmission from Seropositive, Nonviremic Donors to Non-Hepatitis C Liver Transplant Recipients. Hepatology, 67, 1673-1682. https://doi.org/10.1002/hep.29704
|
[13]
|
Luckett, K., Kaiser, T.E., Bari, K., et al. (2019) Use of Hepatitis C Virus Antibody-Positive Donor Livers in Hepatitis C Nonviremic Liver Transplant Recipients. Journal of the American Col-lege of Surgeons, 228, 560-567.
https://doi.org/10.1016/j.jamcollsurg.2018.12.004
|
[14]
|
Bohorquez, H., Bugeaud, E., Bzowej, N., et al. (2021) Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care. Liver Transplantation, 27, 548-557.
https://doi.org/10.1002/lt.25925
|
[15]
|
Kuntzen, C. and Bagha, Z. (2022) The Use of Hepatitis C Virus-Positive Organs in Hepatitis C Virus-Negative Recipients. Clinical Liver Disease, 26, 291-312. https://doi.org/10.1016/j.cld.2022.01.012
|
[16]
|
Nair, S.P., Marella, H.K., Maliakkal, B., et al. (2021) Transplanta-tion of Liver from Hepatitis C-Infected Donors to Hepatitis C RNA-Negative Recipients: Histological and Virologic Outcome. Clinical Transplantation, 35, e14281.
https://doi.org/10.1111/ctr.14281
|
[17]
|
Whitcomb, E., Choi, W.T., Jerome, K.R., et al. (2017) Biopsy Specimens from Allograft Liver Contain Histologic Features of Hepatitis C Virus Infection after Virus Eradication. Clinical Gas-troenterology and Hepatology, 15, 1279- 1285. https://doi.org/10.1016/j.cgh.2017.04.041
|
[18]
|
Anwar, N., Kaiser, T.E., Bari, K., et al. (2020) Use of Hepatitis C Nucleic Acid Test-Positive Liver Allografts in Hepatitis C Virus Sero-negative Recipients. Liver Transplantation, 26, 673-680. https://doi.org/10.1002/lt.25741
|
[19]
|
Barsoum, R.S., William, E.A. and Khalil, S.S. (2017) Hepatitis C and Kidney Disease: A Narrative Review. Journal of Advanced Re-search, 8, 113-130. https://doi.org/10.1016/j.jare.2016.07.004
|
[20]
|
Narang, T.K., Ahrens, W. and Russo, M.W. (2010) Post-Liver Transplant Cholestatic Hepatitis C: A Systematic Review of Clinical and Pathological Findings and Application of Consensus Criteria. Liver Transplantation, 16, 1228- 1235. https://doi.org/10.1002/lt.22175
|
[21]
|
Verna, E.C., Abdelmessih, R., Salomao, M.A., Lefkowitch, J., Moreira, R.K. and Brown, R.S. (2013) Cholestatic Hepatitis C Following Liver Transplantation: An Outcome-Based Histologi-cal Definition, Clinical Predictors, and Prognosis. Liver Transplantation, 19, 78-88. https://doi.org/10.1002/lt.23559
|
[22]
|
Satapathy, S.K., Sclair, S., Fiel, M.I., Del Rio Martin, J. and Schiano, T. (2011) Clinical Characterization of Patients Developing Histologically-Proven Fibrosing Cholestatic Hepatitis C Post-Liver Transplantation. Hepatology Research, 41, 328-339. https://doi.org/10.1111/j.1872-034X.2011.00781.x
|
[23]
|
Ting, P.S., Hamilton, J.P., Gurakar, A., et al. (2019) Hepatitis C-Positive Donor Liver Transplantation for Hepatitis C Seronegative Recipients. Transplant Infectious Dis-ease, 21, e13194. https://doi.org/10.1111/tid.13194
|
[24]
|
Terrault, N.A., Burton, J., Ghobrial, M., et al. (2021) Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors. Hepatology, 73, 2110-2123.
https://doi.org/10.1002/hep.31551
|
[25]
|
Murali, A.R., Chandra, S., Stewart, Z., et al. (2016) Graft Versus Host Disease after Liver Transplantation in Adults: A Case Series, Review of Literature, and an Approach to Management. Transplantation, 100, 2661-2670.
https://doi.org/10.1097/TP.0000000000001406
|
[26]
|
Cheung, M., Walker, A.J., Hudson, B.E., et al. (2016) Out-comes after Successful Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C and Decompensated Cirrhosis. Journal of Hepatology, 65, 741-747.
https://doi.org/10.1016/j.jhep.2016.06.019
|
[27]
|
Belli, L.S., Berenguer, M., Cortesi, P.A., et al. (2016) Delisting of Liver Transplant Candidates with Chronic Hepatitis C after Viral Eradication: A European Study. Journal of Hepa-tology, 65, 524-531.
https://doi.org/10.1016/j.jhep.2016.05.010
|
[28]
|
Emamaullee, J.A., Bral, M., Meeberg, G., et al. (2019) HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation. Canadian Journal of Gastroenterology and Hepatology, 2019, Article ID: 2509059. https://doi.org/10.1155/2019/2509059
|
[29]
|
Saberi, B., Hamilton, J.P., Durand, C.M., et al. (2018) Utilization of Hepatitis C Virus RNA-Positive Donor Liver for Transplant to Hepatitis C Virus RNA-Negative Recipient. Liver Transplantation, 24, 140-143.
https://doi.org/10.1002/lt.24838
|
[30]
|
Selzner, N. and Berenguer, M. (2018) Should Organs from Hepatitis C-Positive Donors Be Used in Hepatitis C-Negative Recipients for Liver Transplantation. Liver Transplantation, 24, 831-840. https://doi.org/10.1002/lt.25072
|
[31]
|
Hori, T., Onishi, Y., Kamei, H., et al. (2016) Fibrosing Cholestatic Hepatitis C in Post-Transplant Adult Recipients of Liver Transplantation. Annals of Gastroenterology, 29, 454-459. https://doi.org/10.20524/aog.2016.0069
|
[32]
|
Bethea, E., Arvind, A., Gustafson, J., et al. (2020) Immediate Ad-ministration of Antiviral Therapy after Transplantation of Hepatitis C-Infected Livers into Uninfected Recipients: Implications for Therapeutic Planning. American Journal of Transplantation, 20, 1619-1628. https://doi.org/10.1111/ajt.15768
|
[33]
|
Levitsky, J., Verna, E.C., et al. (2016) Perioperative Ledipas-vir-Sofosbuvir for HCV in Liver-Transplant Recipients. The New England Journal of Medicine, 375, 2106-2108. https://doi.org/10.1056/NEJMc1611829
|
[34]
|
Kapila, N., Menon, K., Al-Khalloufi, K., et al. (2020) Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus-Negative Recipients: A Real-World Experience. Hepatology, 72, 32-41.
https://doi.org/10.1002/hep.31011
|
[35]
|
朱倩, 张明媛, 牛俊奇. 直接抗病毒药物治疗HCV相关肝细胞癌肝移植受者的研究进展[J]. 临床肝胆病杂志, 2021, 37(10): 2444-2447.
|
[36]
|
Cotter, T.G., Aronsohn, A., Reddy, K.G. and Charlton, M. (2021) Liver Transplantation of HCV-Viremic Donors into HCV-Negative Recipients in the United States: Increasing Frequency with Profound Geographic Variation. Transplantation, 105, 1285-1290. https://doi.org/10.1097/TP.0000000000003382
|
[37]
|
Chhatwal, J., Samur, S., Bethea, E.D., et al. (2018) Trans-planting Hepatitis C Virus-Positive Livers into Hepatitis C Virus-Negative Patients with Preemptive Antiviral Treat-ment: A Modeling Study. Hepatology, 67, 2085-2095.
https://doi.org/10.1002/hep.29723
|